Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 2/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312927 | 1.00 | HINT1 (0.59) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL17485744 | 0.95 | HINT1 (0.56) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL17485745 | 0.93 | TK2 (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL5011969 | 0.89 | HINT1 (0.59) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL27352 | 0.87 | HINT1 (0.59) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL27351 | 0.87 | HINT1 (0.59) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL26630706 | 0.86 | HINT1 (0.60) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL26630708 | 0.86 | HINT1 (0.60) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL16359959 | 0.86 | HINT1 (0.60) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL25757899 | 0.86 | HINT1 (0.60) | HINT1TAS1R3TAS1R1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180094260-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | KASTLE THERAPEUTICS, LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170355986-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | KASTLE THERAPEUTICS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150232838-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | COMERICA BANK | 2015-08-20 | — | — | US | disclosed |
| US-20150167008-A1 | ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2365094-B1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20150105440-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | GENZYME CORPORATION (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2174945-B1 | Antisense modulation of apolipoprotein B expression | GENZYME CORP (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8853178-B2 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-5985664-A | ANTISENSE OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS ENCODING SENTRIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981732-A | ANTISENSE OLIGONUCLEOTIDES WHICH TARGET THE EXPRESSION OF A G PROTEIN | ISIS PHARMACEUTICALS INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977341-A | Antisense modulation of inhibitor-kappa B kinase-beta expression | ISIS PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5962673-A | ANTISENSE AGENT 8 TO 30 NUCLEOBASES IN LENGTH; FOR DIAGNOSIS AND TREATMENT OF ASTHMA, MYASTHENIA GRAVIS, GRAVES' DISEASE, ALLOGRAFT REJECTION, PSORIASIS AND OTHERS; ANTITUMOR/ ANTIPROLIFERATIVE/ANTIDIABETIC/ANTIARTHRITIC AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |